Sai Life Sciences announced strong financial results for Q2 FY26 and H1 FY26, driven by robust growth in both CRO and CDMO services. Revenue increased by 36% in Q2 FY26 and 53% in H1 FY26. EBITDA also saw substantial growth, up by 43% in Q2 FY26 and 101% in H1 FY26. Net profit soared by 100% in Q2 FY26 and 414% in H1 FY26.
Financial Highlights
Sai Life Sciences reported significant growth in revenue and profitability for both the second quarter (Q2 FY26) and the first half (H1 FY26) of fiscal year 2026.
Q2 FY26 Performance
Key financial results for Q2 FY26 compared to Q2 FY25 include:
- Revenue from Operations: Increased by 36% to ₹537 Cr (from ₹396 Cr).
- EBITDA: Rose by 43% to ₹156 Cr (from ₹109 Cr), with a margin of 29%.
- PBT: Increased by 104% to ₹112 Cr (from ₹55 Cr).
- PAT: Soared by 100% to ₹84 Cr (from ₹42 Cr), resulting in a margin of 16%.
H1 FY26 Performance
Key financial results for H1 FY26 compared to H1 FY25 include:
- Revenue from Operations: Increased by 53% to ₹1034 Cr (from ₹675 Cr).
- EBITDA: Grew by 101% to ₹281 Cr (from ₹140 Cr), with a margin of 27%.
- PBT: Surged by 422% to ₹193 Cr (from ₹37 Cr).
- PAT: Jumped by 414% to ₹144 Cr (from ₹28 Cr), resulting in a margin of 14%.
Business Updates
Sai Life Sciences has made significant progress in several areas:
- New Technologies and Modalities: Enhanced capabilities in peptides, photo-flow chemistry, and bioconjugation, including building OEB-6 labs for Discovery and CMC.
- Audits: Successfully completed 35 customer and regulatory audits with zero data integrity deviations.
- Capacity Expansion: Completed phase 2 expansion of Vivarium, adding 12,000 sq. ft. to the Hyderabad R&D Centre.
- Strategic Partnerships: Partnered with Agility Life Sciences (UK) and Centrix Pharma (UK) for end-to-end CMC services.
- Sustainability: Validated near-term GHG reduction targets with SBTi.
- Workplace: Signed UN Women’s Empowerment Principles (WEPs).
Management Commentary
Mr. Krishna Kanumuri, Managing Director and CEO, commented on the company’s strong performance, attributing it to healthy demand across discovery, development, and manufacturing services. Consistent execution, growing client relationships, and traction in late-stage programs contributed to the results.
Earnings Call Information
Sai Life Sciences will host an earnings call on November 7, 2025, at 4:00 PM (IST) to discuss the results. Dial-in numbers and pre-registration details are available for participation.
Source: BSE
